Technology
Health
Biotechnology
Ascendis Pharma
$123.229876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.9876543210-$,.
$123.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
-$1.17 (-0.94%) Today
$0.00 (0.00%) After Hours
Why Robinhood?
You can buy or sell ASND and other stocks, options, ETFs, and crypto commission-free!
About
Ascendis Pharma A/S American Depositary Shares, also called Ascendis Pharma, is a biopharmaceutical company, which engages in the development of drug candidates. Through its TransCon technology, it develops a pipeline of sustained release prodrug therapies including endocrinology product candidates to support the market. Read More The company was founded by Jan Moller Mikkelsen and Harald Rau in September 2006 and is headquartered in Hellerup, Denmark.
Employees
121
Headquarters
Hellerup, Capital Region
Founded
2006
Market Cap
5.23B
Price-Earnings Ratio
—
Dividend Yield
0.00
Average Volume
182.16K
High Today
$125.04
Low Today
$121.99
Open Price
$123.62
Volume
225.59K
52 Week High
$131.76
52 Week Low
$53.21
Collections
Technology
Health
Biotechnology
Biopharmaceutical
Pharmaceutical
Europe (Non-UK)
Europe
News
Yahoo FinanceMar 12
What Makes Ascendis Pharma A/S (ASND) a New Buy Stock
Ascendis Pharma A/S (ASND) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices. The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system. ...
Markets InsiderMar 12
Ascendis Pharma - It's Been All About Growth...
(RTTNews) - Shares of Ascendis Pharma A/S (ASND) closed yesterday's trading at an all-time high of $125.29, and that represents a gain of nearly 100% year-to-date.
Seeking AlphaMar 9
Ascendis Proves Technology Platform With Big Win In Major Indication
Recently, Ascendis Pharma (ASND) announced positive results from its phase 3 Growth Hormone Deficiency (GHD) study. Specifically, its TransCon human growth hormone (hGH) met the primary endpoint in children with growth hormone deficiency (GHD). The main goal was to see if TransCon hGH could prove to be non-inferior to standard daily injection treatment with Genotropin. This provides patients a new option and a more superior way to improve their lives. These results are substantial and this is only the begin...
Price Paid on Robinhood
18% Higher
Right Now
52 Week Low
$53.21
Average Price Paid
$104.53
52 Week High
$131.76
Earnings
-$1.25
-$0.85
-$0.44
-$0.04
Q2 2017
Q3 2017
Q4 2017
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
—
Actual
Expected Mar 27, After Hours